Immuneering Data Suggests Atebimetinib May Overcome MAPK Pathway Resistance
Event summary
- Immuneering will present molecular data on atebimetinib at the 2026 AACR Annual Meeting, highlighting its potential to shrink tumors durably.
- Analysis of ctDNA from ≥64 patients shows rare acquired MAPK pathway alterations with atebimetinib treatment.
- Poster presentation scheduled for April 20, 2026, during the 'Targeting Drug Resistance 2: RAS Signaling' session.
- Immuneering expects to dose the first patient in mid-2026 for the Phase 3 MAPKeeper 301 trial in pancreatic cancer.
The big picture
Immuneering’s data challenges the limitations of conventional MAPK pathway inhibitors, which often face resistance due to tumor mutations. If validated, atebimetinib’s approach could reshape treatment paradigms for RAS-mutant solid tumors, particularly in pancreatic cancer. The upcoming Phase 3 trial will be critical in determining its commercial potential.
What we're watching
- Clinical Validation
- Whether atebimetinib’s Deep Cyclic Inhibition mechanism can sustain durable tumor shrinkage in larger trials.
- Regulatory Pathway
- The pace at which Immuneering advances atebimetinib through Phase 3 trials and potential approvals.
- Competitive Positioning
- How Immuneering differentiates atebimetinib from existing MAPK pathway inhibitors in the oncology market.
Related topics